Biotechnology

Tuesday Feb 06, 2024 - 2:43 pm

InvestorNewsBreaks – H.C. Wainwright & Co. Reiterates ‘Buy’ Rating, $6 PT on Longeveron (NASDAQ: LGVN)

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, was spotlighted in a recent H.C. Wainwright & Co. research report after the Company’s announcement about receiving a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”) for a patent application related to the use of Lomecel-B(TM) in Aging-related Frailty sufferers receiving vaccines for conditions such as…

Tuesday Feb 06, 2024 - 11:52 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Court of Appeal Dismisses Motion Brought by Dr. Raza Bokhari

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders. The company today announced that the Court of Appeal for Ontario affirmed the judgment entered by the Superior Court of Justice in the amount of CDN $2.81 million, plus $175,000, plus interest. FSD…

Tuesday Feb 06, 2024 - 11:28 am

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation at This Month’s BIO CEO & Investor Conference

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be represented at the upcoming BIO CEO & Investor Conference. The conference is scheduled for Feb. 26–27, 2024, in New York City. According to the company, CFO Ryan Confer will present at the two-day event. His presentation, which will begin at 1:30 p.m. ET on Feb.…

Tuesday Feb 06, 2024 - 9:45 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Discusses MS Trial Results During Latest Proactive Interview

Clene (NASDAQ: CLNN) CEO Rob Etherington was the featured guest on a recent Proactive interview. According to an announcement, Etherington joined Proactive host Steve Darling to discuss recent news the company has released regarding results from its long-term, open-label extension (“LTE”) of the VISIONARY-MS trial. Clene is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases,…

Monday Feb 05, 2024 - 11:39 am

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Phase2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has enrolled and dosed the first patient in the phase 2a expansion portion of its Acclaim-1 clinical study of Reqorsa(R) therapy (quaratusugene ozeplasmid). The study combines Genprex’s proprietary lead product candidate with AstraZeneca's Tagrisso(R) to treat patients with late-stage non-small cell lung cancer (“NSCLC”). An open-label, multicenter phase 1/2…

Monday Feb 05, 2024 - 11:08 am

InvestorNewsBreaks – NextPlat Corp. (NASDAQ: NXPL) Announces Upcoming Launch and Expansion of OPKO Health-Branded Storefront

NextPlat (NASDAQ: NXPL, NXPLW), a global e-Commerce provider, is preparing for the launch of its exclusive OPKO Health-branded storefront on Alibaba Group Holding Limited's ("Alibaba")(NYSE: BABA) Tmall Global in China. The move follows the company’s receipt of the initial set of approvals required to operate the store in the country. “We are pleased to reach this strategic milestone with our partners OPKO and Alibaba because…

Friday Feb 02, 2024 - 12:30 pm

InvestorNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Produces ‘Significant and Very Promising Effect’ in Parkinson’s, MS Patients

Clene’s (NASDAQ: CLNN) lead drug candidate CNM-Au8 was the subject of two Phase 2a clinical trials, REPAIR-PD and REPAIR-MS, which evaluated the effects of CNM-Au8 on brain energy metabolite levels in participants with diagnoses of idiopathic Parkinson’s Disease (“PD”) and relapsing Multiple Sclerosis (“MS”), respectively. The REPAIR-PD and REPAIR-MS Phase 2 trials expanded the documented evidence of CNM-Au8’s positive effects demonstrated by in vitro studies,…

Friday Feb 02, 2024 - 10:27 am

InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY, SIGYD) Announces Implementation of a 1-for-40 Reverse Split

Sigyn Therapeutics (OTCQB: SIGY, SIGYD), a development-stage medical technology company, announced the completion of a 1-for-40 reverse split of its common stock. According to the announcement, the reverse split was implemented on Jan. 31, 2024. “As a result of the split, the company’s common stock will trade under the ticker symbol SIGYD for 20 business days and subsequently revert to trading under its historic symbol…

Tuesday Jan 30, 2024 - 12:38 pm

InvestorNewsBreaks — Astiva Health Featured in Bell2Bell Podcast

Astiva Health, which is rapidly making its mark in the Medicare Advantage Prescription Drug (“MAPD”) sector with its commitment to transforming personalized and comprehensive healthcare, was featured in the latest episode of the Bell2Bell Podcast, a part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Dr. Tri T. Nguyen, the co-founder and CEO of Astiva Health, joined the program to…

Tuesday Jan 30, 2024 - 12:03 pm

InvestorNewsBreaks – IBN, BioMedWire to Serve as Official Media Partners for BioPharma Nexus Events

IBN (“InvestorBrandNetwork”), a multifaceted financial news and publishing company, has announced its media collaboration with BioPharma Nexus for upcoming events in 2024. BioMedWire, a specialized communications platform dedicated to the life sciences sector and a vital component of IBN’s Dynamic Brand Portfolio, will also serve as an official media partner for the events. Renowned for its expertise in life sciences, BioPharma Nexus organizes industry leading…

Tuesday Jan 30, 2024 - 9:48 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Names New Board Member, Reports on Corporate Updates

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has appointed Dr. Sanjiv Chopra to its board of directors. According to the announcement. Chopra will be replacing Nitin Kaushal, who resigned from his position. A professor of medicine and former faculty dean for continuing medical education at Harvard Medical School, Dr. Sanjiv…

Tuesday Jan 30, 2024 - 9:42 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Information on $4M Public Offering Pricing

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced the pricing of its public offering. According to the announcement, the “reasonable best efforts” public offering involves participation from healthcare-focused institutional investors and certain officers and directors of the company. The offering is comprised of the purchase and…

Friday Jan 26, 2024 - 2:25 pm

InvestorNewsBreaks – Astrotech Corporation’s (NASDAQ: ASTC) Pro-Control-1000(TM) Line Poised to Help Manufacturers Improve Profits, Yields

Astrotech (NASDAQ: ASTC ), an instrumentation company focused on commercializing its proprietary ATi Mass Spectrometer Technology(TM) that is now used in airports and agriculture applications throughout the world, continues to expand its technology into new markets. “Astrotech has announced the introduction of its newest Pro-Control-1000(TM) product line of instrumentation designed to improve chemical manufacturing efficiencies. Astrotech is also announcing the creation of its newest wholly…

Friday Jan 26, 2024 - 1:26 pm

InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Dedicated to Enhancing Quality of Life for Individuals Living with ASD

PaxMedica (NASDAQ: PXMD) recently released an insightful video detailing the outcomes of its Phase 2 study on autism spectrum disorder (“ASD”), initially published in the Annals of General Psychiatry. “This pivotal video highlights the research led by Chief Medical Officer Dr. David Hough and a team of ASD experts, and the potential of low-dose suramin intravenous infusions as a breakthrough treatment for ASD… Focused on…

Thursday Jan 25, 2024 - 2:31 pm

InvestorNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Announces Results of Special Meeting

Renovaro BioSciences (NASDAQ: RENB), a biotechnology corporation focusing on cell, gene and immunotherapy, has announced the results of its special meeting of shareholders (“special meeting”) held at 12:00 p.m. ET on Jan. 25, 2024. According to the announcement, all matters put forward before the company’s shareholders for consideration and approval, as set out in Renovaro’s definitive proxy statement dated Jan. 3, 2024, were approved by…

Thursday Jan 25, 2024 - 1:33 pm

InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Scientific Research Collaborator Receives Prestigious Louis-Jeantet Prize

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products, is congratulating its colead scientific research collaborator Professor Dr. Dirk Görlich, who is this year’s Louis-Jeantet Prize recipient. A director at the Max Planck Institute for Multidisciplinary Sciences (“MPI-NAT”), Görlich and his colleague Dr. Matthias Dobbelstein, from the University Medical Center Göttingen (“UMG”), lead teams that have collaborated with Scinai in the discovery…

Wednesday Jan 24, 2024 - 3:15 pm

InvestorNewsBreaks – Why Sigyn Therapeutics Inc. (SIGY) Is ‘One to Watch’

Sigyn Therapeutics (OTCQB: SIGY, SIGYD) is a development-stage medical technology company whose therapeutic candidates include Sigyn Therapy(TM), the ImmunePrep(TM) platform, ChemoPrep(TM), and ChemoPure(TM). “The company is advancing Sigyn Therapy to treat pathogen-associated inflammatory disorders that are not addressed with FDA-approved drugs. Candidate treatment indications include community-acquired pneumonia, drug-resistant virus and bacterial infections, endotoxemia, and sepsis, which is the leading cause of hospital deaths in the…

Friday Jan 19, 2024 - 9:56 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) CEO to Present at January Water Tower Research Fireside Chat

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, announced that CEO Eric A Adams will be participating in the upcoming Water Tower Research Fireside Chat Series. This month’s chat is scheduled to begin at 1 p.m. ET on Jan. 25, 2024. According to the announcement, topics discussed during the event will include an overview…

Tuesday Jan 16, 2024 - 1:37 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Provides Update on Litigation

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today provided an update regarding its litigation with GBB Drink Lab Inc. (“GBB”). In May 2023, GBB filed a lawsuit against FSD Pharma alleging a material breach of a mutual nondisclosure agreement and trade secret misappropriation. FSD Pharma has categorically denied these allegations…

Tuesday Jan 16, 2024 - 12:22 pm

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Business Update, Milestones

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today outlined key accomplishments from 2023 and provided key strategic priorities for 2024. “In 2023, we experienced significant progress in both InMed’s pharmaceutical drug development and in BayMedica’s health and wellness initiatives. Our primary accomplishments throughout the year included a number of key milestones, such as…

Tuesday Jan 16, 2024 - 12:17 pm

InvestorNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Releases CEO Shareholder Message

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has released a message for its shareholders from CEO Mark Dybul. In the message, Dybul provides an update about key developments the company experienced during 2023, including signing a definitive agreement to combine with the European-based, cutting-edge artificial-intelligence (“AI”) company GEDi Cube; GEDi Cube’s partnership…

Friday Jan 12, 2024 - 1:00 pm

InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) on Promising Path to Address Unmet ASD Needs

PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focused on developing novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. “While ASD is not uncommon, there are no pharmaceutical treatments approved to treat the disorder, only to manage the symptoms – which creates an unmet need in the industry… PaxMedica is on a mission…

Tuesday Jan 09, 2024 - 11:24 am

InvestorNewsBreaks – Branded Legacy Inc. (BLEG) Acquires All In Extracts LLC

Branded Legacy (OTC: BLEG), (soon to be known as Royal Enterprises Inc.), a burgeoning company in the pharmaceutical biotechnology sector, today announced its strategic acquisition of All In Extracts, a pioneering entity focused on medicinal ethnobotany. The milestone deal amplifies Branded Legacy’s focus on innovation, expansion and collaborative growth within the biotech community. “As soon as I met with the All In team, I knew…

Monday Jan 08, 2024 - 11:11 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Significant Positive Results from LTE VISIONARY-MS Trial

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including (“ALS”) and multiple sclerosis (“MS”), today reported new CNM-Au8(R) results from the long-term open label extension (“LTE”) of the VISIONARY-MS trial in participants with stable relapsing multiple sclerosis (“RMS”) totaling nearly…

Friday Jan 05, 2024 - 10:44 am

InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Closes on $1.69M Exercise of Outstanding Warrants

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused both on development of inflammation and immunology (“I&I”) biological therapeutic products and provision of boutique CDMO services, has closed on its previously announced exercise of certain outstanding warrants. The exercise involved the purchase of up to 2,606,552 American Depositary Shares (“ADSs”), with each share representing 400 ordinary shares. According to the announcement, the shares had exercise prices ranging…

Thursday Jan 04, 2024 - 12:19 pm

InvestorNewsBreaks – Profound Medical Corp. (TSX: PRN) (NASDAQ: PROF) Announces Pricing of US$20M Public Offering

Profound Medical (TSX: PRN) (NASDAQ: PROF) recently announced the pricing of its underwritten public offering of 2,666,667 common shares, each at a price to the public of US$7.50, led by health care-focused institutional investors. Of approximately US$20,000,000 in gross proceeds from the offering, the company intends to use net proceeds to fund the continued commercialization of the TULSA-PRO(R) system in the United States, to fund…

Thursday Jan 04, 2024 - 9:35 am

InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY) CEO Releases Shareholder Letter Outlining Opportunities, Challenges, Processes

Sigyn Therapeutics (OTCQB: SIGY, SIGYD), a development-stage medical technology company, has released a shareholder letter from chair and CEO Jim Joyce. In the letter, whose objective is to help shareholders better understand SIGY opportunities, challenges and decision-making processes, Joyce reiterates the company’s long-term objective of building an enduring organization whose therapies save lives. The letter included an update on the company’s proposed underwritten financing and…

Tuesday Jan 02, 2024 - 9:56 am

InvestorNewsBreaks – Branded Legacy Inc. (BLEG) Announces Retirement of Additional 442M Common Shares

Branded Legacy (OTC: BLEG), further highlighting its commitment to shareholders and future growth, today announced the final retirement of an additional 442 million common shares, bringing the total shares retired to an extraordinary 2.44 billion. The action surpasses the initial commitment and underscores Branded Legacy’s unwavering dedication to shareholder value. According to the announcement, the retirements have resulted in management now owning zero common stock,…

Friday Dec 29, 2023 - 10:44 am

InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Agreement for Million-Dollar Exercise of Outstanding Warrants

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products and provision of boutique CDMO (“CDMO”) services, has entered a definitive agreement for the immediate exercise of outstanding warrants. The agreement outlines the purchase of up to 2,606,552 American Depositary Shares (“ADSs”), with each ADS representing 400 ordinary shares. According to the announcement, exercise prices for…

Thursday Dec 21, 2023 - 12:56 pm

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Enters Definitive Agreement for $2.36M Registered Direct Offering

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has announced a $2.36 million registered direct offering. The company entered into a definitive agreement for the issue and sale of 1,355,301 shares of common stock, priced at $1.745 per share. In addition, the company announced a…

Thursday Dec 21, 2023 - 12:19 pm

InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Files 8-K Following Nasdaq Compliance Achievement

In a significant corporate update, PaxMedica (NASDAQ: PXMD) today filed an 8-K with the Securities and Exchange Commission, disclosing its successful compliance with Nasdaq’s minimum equity requirements. Journey Towards Compliance PaxMedica's compliance journey began on December 6, 2022, when Nasdaq noted its inability to meet the Minimum Market Value of Listed Securities Requirement of $35 million over 30 days. PaxMedica faced potential delisting in June…

Wednesday Dec 20, 2023 - 10:58 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Reports Additional Positive Clinical Data, Imaging Biomarker Results in Phase 2a Lomecel-B(TM) Trial

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-Related Frailty, is releasing new clinical and biomarker results from the CLEAR MIND trial of its investigational product Lomecel-B(TM). The phase 2a trial evaluates Lomecel-B for the treatment of mild Alzheimer’s disease. According to the report, the new data…

Wednesday Dec 20, 2023 - 9:44 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Approves Election of Directors During 2023 Annual General Meeting

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, is reporting on the results of its 2023 annual general meeting. According to the report, during the meeting, which was held on Dec. 19, 2023, all matters considered by shareholders were approved; agenda items were sent to shareholders in a notice of meeting and management…

Thursday Dec 14, 2023 - 3:31 pm

InvestorNewsBreaks – Why SOHM Inc. (SHMN) Is ‘One to Watch’

SOHM (OTC: SHMN) is a recognized generic pharmaceutical manufacturer with operations spanning India, the Philippines, Uganda, the U.S., U.K. and EU. The company aims to create and produce cutting-edge generic medications that span a wide range of treatment areas, all while ensuring top-tier quality and keeping prices affordable. “With proficiency in both manufacturing and marketing, SOHM stands out. The company holds licenses for producing over…

Monday Dec 11, 2023 - 10:45 am

InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announced Peer-Reviewed Journal Publishes Data Supporting NanoAbs

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products, is announcing the publication of a peer-reviewed article regarding NanoAbs. The article reports on data that supports the use of Scinai's aerosolized NanoAbs as a platform for the treatment of hyperinflammatory viral diseases, which addresses significant medical needs. Titled “Nanobodies to multiple spike variants and inhalation…

Friday Dec 08, 2023 - 2:44 pm

InvestorNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) Long-Term Follow-Up Data Shows Significantly Improved Survival in ALS Patients

Clene (NASDAQ: CLNN), together with its wholly owned subsidiary Clene Nanomedicine Inc., recently provided operating highlights for its amyotrophic lateral sclerosis (“ALS”) clinical program. “In August, Clene reported a 24-month long-term data cut from the open-label extension (‘OLE’) of the RESCUE-ALS study as of July 2023, which showed a significant median survival benefit of 19.3 months in addition to a significant (p=0.049) 52% decreased risk…

Wednesday Dec 06, 2023 - 11:43 am

InvestorNewsBreaks — Astiva Health Partners with IBN to Deliver Corporate Communications, Increase Awareness

Astiva Health, a leading healthcare provider that specializes in delivering personalized and comprehensive healthcare solutions to diverse communities, has selected IBN, a versatile financial news and publishing company specializing in private and public entities, as a corporate communications partner. According to the announcement, the partnership is designed to enhance Astiva Health's corporate communications initiatives as the company focuses on its mission to deliver unparalleled quality care…

Tuesday Dec 05, 2023 - 2:38 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Closes Non-Brokered Private Placement

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) today announced that it has closed a non-brokered private placement and issued 24 class A multiple voting shares of the company, each at a price of $1.90, for gross proceeds of $45.60 (the “offering”). All securities issued pursuant to the offering are subject to a statutory hold period of four months plus a day from issuance in…

Tuesday Dec 05, 2023 - 12:04 pm

InvestorNewsBreaks – Safety Shot (NASDAQ: SHOT) Releases Updated Report on Litigation

Safety Shot (NASDAQ: SHOT), makers of the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity, is reporting on its newly filed lawsuit against Capybara Research. According to the update, the company filed a federal lawsuit in the U.S. District Court for the Southern District of New York against Capybara Research on Dec. 4, 2023. In…

Monday Dec 04, 2023 - 2:39 pm

InvestorNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Featured in Recent H.C. Wainwright & Co. Research Report with ‘Buy’ Rating, $3 PT

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is spotlighted in a recent H.C. Wainwright & Co. research report. The report “is initiating coverage on PaxMedica, an emerging firm developing novel formulations of suramin for treatment of neurological disorders with intractable symptoms,” which is “attacking autism with a novel approach.” The report noted that PaxMedica was the first company to…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions